Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

18 June 2002

Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.

Nicolas Tsavaris, Christos Kosmas, Haralambos P Kalofonos

Med Sci Monit 2002; 8(6): PI58-63 :: ID: 420797

Abstract

BACKGROUND: Docetaxel has been the only single agent with proven activityand documented survival benefit in the second-line treatment of advanced/refractory non-small cell lungcancer (NSCLC). Combinations of docetaxel with other active agents in this setting, such as gemcitabine,besides their popularity as front-line treatment, are currently being explored in an attempt to improvethe results over single-agent docetaxel in relapsed/refractory NSCLC.MATERIAL/METHODS: Given the establishedactivity of single-agent docetaxel in two recent large randomized phase III trials against best supportivecare or versus single-agent Vinorelbine or Ifosfamide in patients with platinum pretreated NSCLC, andthe proven activity of single-agent gemcitabine in this setting, combination regimens employing thesetwo agents in various doses and schedules have recently been initiated. Adequately designed phase IIstudies using standard criteria of efficacy and safety, with peer-review based publication, were selectedfrom the literature.RESULTS: The gemcitabine/docetaxel combination in various schedules with or withoutG-CSF support as salvage therapy of NSCLC pre-treated with platinum+paclitaxel-based regimens has beenevaluated in four recently published phase II clinical studies, and has been shown to represent a tolerableand active regimen in this setting, yielding a 10-33% response rate, improvement of disease-related symptoms,and meaningful median and 1-year survival figures in the range of 20-32%. Improvement of disease-relatedsymptoms has outweighed toxicity in all these studies.CONCLUSIONS: Randomized studies are warranted,comparing the gemcitabine/docetaxel combination to single-agent gemcitabine or docetaxel, drugs currentlyrecommended in the second-line treatment of advanced NSCLC.

Keywords: Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase II, Deoxycytidine, paclitaxel, Salvage Therapy, Taxoids

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750